Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | FRK | P42685 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3775833 | 0.99 | MAP4K4 (0.52) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL15995520 | 0.91 | MAP4K4 (0.54) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL17407525 | 0.89 | MAP4K4 (0.59) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL9967319 | 0.89 | MAP4K4 (0.45) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL16004750 | 0.88 | MAP4K4 (0.58) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL15995698 | 0.88 | MAP4K4 (0.43) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL23600476 | 0.86 | MAP4K4 (0.58) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL2446819 | 0.86 | MAPK14 (0.45) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL30411917 | 0.85 | MAP4K4 (0.61) | MAP4K4ABL1NTRK1FYNLYN | |
| SCHEMBL17407527 | 0.84 | LYN (0.52) | MAP4K4ABL1NTRK1FYNLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819998-B1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-9278936-B2 | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride | ARRAY BIOPHARMA INC. (US) | 2016-03-08 | — | — | US | claimed |
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2819998-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130573-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | claimed |
| EP-4101844-A1 | CRYSTALLINE FORM OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | Array BioPharma Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101844-A1 | CRYSTALLINE FORM OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | Array BioPharma Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-2819998-B1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790206-B2 | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof | ARRAY BIOPHARMA INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2961744-B1 | INTERMEDIATES FOR USE IN THE PREPARATION OF INDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ARRAY BIOPHARMA INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101415685-A | Kinase inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | CN | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | ARRAY BIOPHARMA, INC. | 2009-01-22 | — | — | US | disclosed |
| EP-1981851-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | TTR, HK1, REN | MAP4K4 3141/4885ABL1 462/4885NTRK1 3592/4885 |
| US-20090023795-A1 | Kinase Inhibitors And Methods Of Use Thereof | MAP3K1, MAP3K19, MAP3K20 | MAP4K4 31/4885ABL1 28/4885NTRK1 807/4885 |
| US-20100331385-A1 | PYRAZOLE UREA DERIVATIVES USED AS KINASE INHIBITORS | MAP3K1, MAP3K19, MAP3K13 | MAP4K4 47/4885ABL1 138/4885NTRK1 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.